Back to Search Start Over

Inhibition of class I HDACs attenuates renal interstitial fibrosis in a murine model.

Authors :
Yang, Min
Chen, Gen
Zhang, Xue
Guo, Yuliang
Yu, Yan
Tian, Li
Chang, Sheng
Chen, Zhonghua Klaus
Source :
Pharmacological Research. Apr2019, Vol. 142, p192-204. 13p.
Publication Year :
2019

Abstract

Graphical abstract Abstract Renal interstitial fibrosis is the most common of all the forms of chronic kidney disease (CKD). Research has shown that histone deacetylases (HDACs) participate in the process leading to renal fibrosis. However, the effects of class I HDAC inhibitors on the mechanisms of onset and progression of renal interstitial fibrosis are still unclear. Here, we present the effects and mechanisms of action of FK228 (a selective inhibitor of class I HDACs) in the murine model of unilateral ureteral obstruction (UUO) and in vitro models. We investigated the antifibrotic role of FK228 in a murine model of UUO. We used two key effector cell populations, rat renal interstitial fibroblasts and renal tubular epithelial cells exposed to recombinant transforming growth factor-beta 1 (TGF-β1), to explore the mechanistic pathways among in vitro models. The results indicated that FK228 significantly suppressed the production of extracellular matrix (ECM) in both in vivo and in vitro models. FK228 inhibited renal fibroblast activation and proliferation and increased the acetylation of histone H3. We found that FK228 also inhibited the small mothers against decapentaplegic (Smad) and non-Smad signaling pathways. So FK228 could significantly suppress renal interstitial fibrosis via Smad and non-Smad pathways. FK228 may be the basis for a new and effective medicine for alleviating renal fibrosis in the future. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
10436618
Volume :
142
Database :
Academic Search Index
Journal :
Pharmacological Research
Publication Type :
Academic Journal
Accession number :
135602238
Full Text :
https://doi.org/10.1016/j.phrs.2019.02.011